Andrew W. Pawluczkowycz

发表

Binding of Submaximal C1q Promotes Complement-Dependent Cytotoxicity (CDC) of B Cells Opsonized with Anti-CD20 mAbs Ofatumumab (OFA) or Rituximab (RTX): Considerably Higher Levels of CDC Are Induced by OFA than by RTX1

Paul W. H. I. Parren, P. Parren, J. V. D. van de Winkel, 2009, The Journal of Immunology.

Complement Activation and Complement-Mediated Killing of B Cells Promoted by Anti-CD20 Monoclonal Antibodies (mAb) Rituximab and Ofatumumab Are Rapid, and Ofatumumab Kills Cells More Rapidly and with Greater Efficacy.

P. Parren, Andrew W. Pawluczkowycz, Ronald P. Taylor, 2007 .

Binding of Submaximal C1q to B Cells Opsonized with Anti-CD20 Mabs Ofatumumab (OFA) or Rituximab (RTX) Promotes Complement Dependent Cytotoxicity (CDC), and Considerably Higher Levels of CDC Are Induced by OFA Than by RTX.

P. Parren, Andrew W. Pawluczkowycz, Ronald P. Taylor, 2008 .

Thrice-Weekly Low-Dose Rituximab Decreases CD20 Loss via Shaving and Promotes Enhanced Targeting in Chronic Lymphocytic Leukemia1

Michael E. Williams, A. Kennedy, Andrew W. Pawluczkowycz, 2006, The Journal of Immunology.

Rituximab-CD20 Complexes Are Shaved from Z138 Mantle Cell Lymphoma Cells in Intravenous and Subcutaneous SCID Mouse Models1

Michael E. Williams, Andrew W. Pawluczkowycz, M. Lindorfer, 2007, The Journal of Immunology.

Induced by OFA than by RTX Considerably Higher Levels of CDC Are Ofatumumab (OFA) or Rituximab (RTX): of B Cells Opsonized with Anti-CD20 mAbs Complement-Dependent Cytotoxicity (CDC) Binding of Submaximal C1q Promotes

Paul, Andrew W. Pawluczkowycz, F. Beurskens, 2009 .

Fractionated subcutaneous rituximab is well-tolerated and preserves CD20 expression on tumor cells in patients with chronic lymphocytic leukemia

Thomas E. Hughes, A. Wiestner, Andrew W. Pawluczkowycz, 2010, Haematologica.

Complement activation and C3b deposition on rituximab-opsonized cells substantially blocks binding of phycoerythrin-labeled anti-mouse IgG probes to rituximab.

Michael E. Williams, A. Kennedy, Andrew W. Pawluczkowycz, 2004, Journal of immunological methods.

Complement Activation on B Lymphocytes Opsonized with Rituximab or Ofatumumab Produces Substantial Changes in Membrane Structure Preceding Cell Lysis1

P. Parren, P. Stukenberg, H. Lokhorst, 2008, The Journal of Immunology.

A novel approach to preventing the hemolysis of paroxysmal nocturnal hemoglobinuria: both complement-mediated cytolysis and C3 deposition are blocked by a monoclonal antibody specific for the alternative pathway of complement.

C. Parker, Andrew W. Pawluczkowycz, M. Lindorfer, 2010, Blood.

Selective and efficient inhibition of the alternative pathway of complement by a mAb that recognizes C3b/iC3b.

A. Kennedy, D. DiLillo, Andrew W. Pawluczkowycz, 2006, Molecular immunology.

Hematin Promotes Complement Alternative Pathway-Mediated Deposition of C3 Activation Fragments on Human Erythrocytes: Potential Implications for the Pathogenesis of Anemia in Malaria1

J. Waitumbi, Andrew W. Pawluczkowycz, M. Lindorfer, 2007, The Journal of Immunology.

Binding of Rituximab, Trastuzumab, Cetuximab, or mAb T101 to Cancer Cells Promotes Trogocytosis Mediated by THP-1 Cells and Monocytes1

Andrew W. Pawluczkowycz, M. Lindorfer, P. V. Beum, 2008, The Journal of Immunology.

Complement (C) Activation Followed by Penetration of the Membrane Attack Complex (MAC) on B Cells Opsonized with CD20 Mabs Allows for Calcium Influx Which Induces Streamers. Generalization of Streaming to Include other Mabs and Target Cells.

P. Parren, P. Stukenberg, Andrew W. Pawluczkowycz, 2008 .